<unk> , in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Tafasitamab
Donanemab
Atoltivimab
Naxitamab
Sutimlimab
Obiltoxaximab
Maftivimab
Regdanvimab